03 August 2026
03 August 2026
Of the 62 subjects, 30 had previously failed first-line venetoclax, where published remission rates are about 13%.
Located near Boston, the facility is intended to support assembly, inspection, testing, and manufacturing activities for the eShunt system.
The funding will advance its ATLAS trial, assessing lead candidate [Ac-225]RTX-2358, a FAP-targeted radiotherapeutic for advanced sarcomas.
The eyonis LCS Software as a Medical Device uses AI to help clinicians detect and diagnose lung cancer earlier.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
